Trial Profile

A Phase I/II, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study of Sevuparin/DF02, as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 03 Jan 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sevuparin (Primary) ; Atovaquone/proguanil
Indications Falciparum malaria
Focus Adverse reactions; Therapeutic Use
Sponsors Modus Therapeutics

Most Recent Events

20 Dec 2017 According to a Modus Therapeutics media release, results from this trial have been published in PLOS ONE.
20 Dec 2017 Results presented in a Modus Therapeutics media release.
28 Nov 2014 According to Dilaforette media release, results were presented at the American Society of Tropical Medicine and Hygiene (ASTMH) meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com